Research Article
Non-albicans Candida Infection: An Emerging Threat
Table 3
Antifungal susceptibility profile of Candida isolates.
| | Candida spp. (number of isolates) | Antifungal agent | (%) | SDD (%) | (%) |
| | C. albicans (192) | Amphotericin B | 164 (85.4) | 8 (4.1) | 20 (10.4) | | Fluconazole | 121 (63.1) | 6 (3.1) | 65 (33.8) | | Itraconazole | 116 (60.4) | 2 (1.1) | 74 (38.5) | | Ketoconazole | 112 (45.3) | — | 80 (41.7) |
| | C. tropicalis (116) | Amphotericin B | 98 (84.4) | 9 (7.7) | 9 (7.7) | | Fluconazole | 69 (59.5) | 3 (2.6) | 44 (37.9) | | Itraconazole | 65 (56.1) | 2 (1.7) | 49 (42.2) | | Ketoconazole | 63 (54.3) | 4 (3.5) | 49 (42.2) |
| | C. glabrata (93) | Amphotericin B | 85 (91.3) | — | 8 (8.7) | | Fluconazole | 49 (52.7) | 6 (6.5) | 38 (40.8) | | Itraconazole | 50 (53.8) | — | 43 (46.2) | | Ketoconazole | 51 (54.8) | 2 (2.1) | 60 (64.5) |
| | C. krusei (54) | Amphotericin B | 51 (94.4) | — | 3 (5.6) | | Fluconazole | 34 (62.9) | 1 (1.9) | 19 (35.2) | | Itraconazole | 31 (57.4) | — | 23 (42.6) | | Ketoconazole | 32 (59.2) | 2 (3.7) | 20 (37.1) |
| | C. kefyr (30) | Amphotericin B | 28 (93.3) | — | 2 (6.7) | | Fluconazole | 16 (53.3) | 3 (10) | 11 (36.7) | | Itraconazole | 19 (63.3) | 2 (6.7) | 12 (40) | | Ketoconazole | 16 (53.3) | 3 (10) | 11 (36.7) |
| | C. parapsilosis (18) | Amphotericin B | 15 (83.4) | 2 (11.1) | 1 (5.5) | | Fluconazole | 11 (61.1) | 2 (11.1) | 5 (27.8) | | Itraconazole | 10 (55.5) | 2 (11.1) | 6 (33.4) | | Ketoconazole | 11 (61.1) | 2 (11.1) | 5 (27.8) |
| | C. guilliermondii (11) | Amphotericin B | 11 (100) | — | — | | Fluconazole | 7 (63.6) | 2 (18.2) | 2 (18.2) | | Itraconazole | 6 (54.5) | 2 (18.2) | 3 (27.3) | | Ketoconazole | 8 (72.7) | — | 3 (27.3) |
| | C. dubliniensis (9) | Amphotericin B | 9 (93.3) | — | 2 (6.7) | | Fluconazole | 3 (33.3) | 3 (33.3) | 3 (33.3) | | Itraconazole | 4 (44.5) | 2 (22.2) | 3 (33.3) | | Ketoconazole | 3 (33.3) | — | 6 (66.7) |
|
|
